Burden of Chronic Hepatitis B and C Infections in 2015 and Future Trends in Japan: A Simulation Study

Overview

Journal Lancet Reg Health West Pac

Date 2022 May 31

PMID 35637862

Authors

Junko Tanaka

Akemi Kurisu

Masatsugu Ohara

Serge Ouoba

Masayuki Ohisa

Aya Sugiyama

Michelle L Wang

Lindsey Hiebert

Tatsuya Kanto

Tomoyuki Akita

Affiliations

Soon will be listed here.

Abstract

Background: Determining the number of chronic hepatitis B (HBV) and C virus (HCV) infections is essential to assess the progress towards the World Health Organization 2030 viral hepatitis elimination goals. Using data from the Japanese National Database (NDB), we calculated the number of chronic HBV and HCV infections in 2015 and predicted the trend until 2035.

Methods: NDB and first-time blood donors data were used to calculate the number of chronic HBV and HCV infections in 2015. A Markov simulation was applied to predict chronic infections until 2035 using transition probabilities calculated from NDB data.

Findings: The total number of chronic HBV and HCV infections in 2015 in Japan was 1,905,187-2,490,873 (HCV:877,841-1,302,179, HBV:1,027,346-1,188,694), of which 923,661-1,509,347 were undiagnosed or diagnosed but not linked to care ("not engaged in care"), and 981,526 were engaged in care. Chronic HBV and HCV infections are expected to be 923,313-1,304,598 in 2030, and 739,118-1,045,884 in 2035. Compared to 2015, by 2035, the number of persons with HCV not engaged in care will decline by 59·8 - 76·1% and 86·5% for patients in care. For HBV, a 47·3 - 49·3% decrease is expected for persons not engaged in care and a decline of 26·0% for patients engaged in care.

Interpretation: Although the burden of HBV and HCV is expected to decrease by 2035, challenges in controlling hepatitis remain. Improved and innovative screening strategies with linkage to care for HCV cases, and a functional cure for HBV are needed.

Funding: Japan Ministry of Health, Labour and Welfare.

Citing Articles

Association of occupational physical activity and sedentary behaviour with the risk of hepatocellular carcinoma: a case-control study based on the Inpatient Clinico-Occupational Database of Rosai Hospital Group.

Nakazawa S, Fukai K, Sano K, Furuya Y, Hoshi K, Kojimahara N BMJ Open. 2025; 15(3):e092020.

PMID: 40074261 PMC: 11904348. DOI: 10.1136/bmjopen-2024-092020.

Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis.

Ju S, Katsumata M, Mizukami A, Abersone I, Gielen V Dig Dis. 2024; 43(1):63-74.

PMID: 39476809 PMC: 11817863. DOI: 10.1159/000541293.

Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study.

Zhang J, Chen C, Xia Z, Xiong X, Liu P, Xu Y Oncol Lett. 2024; 28(3):410.

PMID: 38988447 PMC: 11234805. DOI: 10.3892/ol.2024.14544.

Safety and feasibility of liver resection including major hepatectomy for geriatric patients with hepatocellular carcinoma: a retrospective observational study.

Kanno H, Hashimoto K, Sakai H, Ogata T, Fukutomi S, Akashi M BMC Cancer. 2024; 24(1):765.

PMID: 38926636 PMC: 11201318. DOI: 10.1186/s12885-024-12514-0.

Survey of Medical Referral by Japanese Dentists for Patients With Hepatitis B, Hepatitis C, and Lichen Planus.

Nagao Y, Tomooka K, Takahashi H Cureus. 2024; 16(5):e60624.

PMID: 38903276 PMC: 11187472. DOI: 10.7759/cureus.60624.

References

Koyama T, Matsuda I, Sato S, Yoshizawa H . Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981-1992) and epidemiological evidence for its efficacy. Hepatol Res. 2003; 26(4):287-292. DOI: 10.1016/s1386-6346(03)00168-2. View

Yamasaki K, Tomohiro M, Nagao Y, Sata M, Shimoda T, Hirase K . Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterol. 2012; 12:139. PMC: 3502559. DOI: 10.1186/1471-230X-12-139. View

Amin J, Law M, Bartlett M, Kaldor J, Dore G . Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006; 368(9539):938-45. DOI: 10.1016/S0140-6736(06)69374-4. View

. The case for simplifying and using absolute targets for viral hepatitis elimination goals. J Viral Hepat. 2020; 28(1):12-19. DOI: 10.1111/jvh.13412. View

Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J . Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011; 54(4):185-95. DOI: 10.1159/000324525. View

. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020; 50(7):791-816. DOI: 10.1111/hepr.13503. View

Moriya T, Koyama T, Tanaka J, Mishiro S, Yoshizawa H . Epidemiology of hepatitis C virus in japan. Intervirology. 1999; 42(2-3):153-8. DOI: 10.1159/000024974. View

Revill P, Chisari F, Block J, Dandri M, Gehring A, Guo H . A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019; 4(7):545-558. PMC: 6732795. DOI: 10.1016/S2468-1253(19)30119-0. View

Wen W, Chen H, Ni Y, Hsu H, Kao J, Hu F . Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology. 2011; 53(2):429-36. DOI: 10.1002/hep.24061. View

10.

Tanaka J, Kumada H, Ikeda K, Chayama K, Mizui M, Hino K . Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol. 2003; 70(3):378-86. DOI: 10.1002/jmv.10406. View

11.

Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J . Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatol Res. 2021; 52(1):81-92. DOI: 10.1111/hepr.13723. View

12.

Ujiie M, Sasaki K, Yoshikawa N, Enami T, Shobayashi T . Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan. Lancet Infect Dis. 2016; 16(12):1325. DOI: 10.1016/S1473-3099(16)30463-7. View

13.

Noto H, Terao T, Ryou S, Hirose Y, Yoshida T, Ookubo H . Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980-1994. J Gastroenterol Hepatol. 2003; 18(8):943-9. DOI: 10.1046/j.1440-1746.2003.03092.x. View

14.

Sato T, Huy Do S, Asao T, Akita T, Katayama K, Tatara K . Estimating numbers of persons with persistent hepatitis B virus infection transmitted vertically and horizontally in the birth cohort during 1950-1985 in Japan. Hepatol Res. 2013; 44(10):E181-8. DOI: 10.1111/hepr.12288. View

15.

Uchida S, Satake M, Kurisu A, Sugiyama A, Ko K, Akita T . Incidence rates of hepatitis C virus infection among blood donors in Japan: a nationwide retrospective cohort study. Transfusion. 2018; 58(12):2880-2885. DOI: 10.1111/trf.14951. View

16.

Tanaka J, Akita T, Ko K, Miura Y, Satake M . Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view. Hepatol Res. 2019; 49(9):990-1002. PMC: 6852166. DOI: 10.1111/hepr.13417. View

17.

Yamasaki K, Tanaka J, Kurisu A, Akita T, Ohisa M, Sakamune K . Natural course of persistent hepatitis B virus infection in hepatitis B e antigen-positive and hepatitis B e antigen-negative cohorts in Japan based on the Markov model. J Med Virol. 2018; 90(12):1800-1813. DOI: 10.1002/jmv.25260. View

18.

Zoratti M, Siddiqua A, Morassut R, Zeraatkar D, Chou R, Holten J . Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine. 2020; 18:100237. PMC: 6948236. DOI: 10.1016/j.eclinm.2019.12.007. View

19.

Tanaka J, Mizui M, Nagakami H, Katayama K, Tabuchi A, Komiya Y . Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology. 2008; 51(1):33-41. DOI: 10.1159/000118794. View

20.

Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M . Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336(26):1855-9. DOI: 10.1056/NEJM199706263362602. View